YCYu Chen

Yu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu Chen has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2

    by Oleksandra Herasymenko, Madhushika Silva, Galen J. Correy, Abd Al-Aziz A. Abu-Saleh, Suzanne Ackloo, Cheryl Arrowsmith, Fuqiang Ban, Hartmut Beck, Kevin P. Bishop, Hugo J. Bohórquez, et al.

    The third Critical Assessment of Computational Hit-finding Experiments (CACHE) challenged computational teams to identify chemically novel ligands targeting the macrodomain 1 of SARS-CoV-2 Nsp3, a promising coronavirus drug target. Twenty-three groups deployed diverse design strategies to collectively select 1739 ligand candidates. While over 85% of the designed molecules were chemically novel, the best experimentally confirmed hits were structurally similar to previously published compounds. Confirming a trend observed in CACHE #1 and #2, two of the best-performing workflows used compounds selected by physics-based computational screening methods to train machine learning models able to rapidly screen large chemical libraries, while four others used exclusively physics-based approaches. Three pharmacophore searches and one fragment growing strategy were also part of the seven winning workflows. While active molecules discovered by CACHE #3 participants largely mimicked the adenine ring of the endogenous substrate, ADP-ribose, preserving the canonical chemotype commonly observed in previously reported Nsp3-Mac1 ligands, they still provide novel structure-activity relationship insights that may inform the development of future antivirals. Collectively, these results show that multiple molecular design strategies can efficiently converge on similar effective molecules.

  • Open Access

    Mind the Gap—Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence

    by Theresa Noonan, Katrin Denzinger, Valerij Talagayev, Yu Chen, Kristina Puls, Clemens Alexander Wolf, Sijie Liu, Trung Ngoc Nguyen, Gerhard Wolber

    G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. Three-dimensional pharmacophore models are powerful computational tools in in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, the discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and the elucidation of ligand–receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning are highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.


  • Open Access

    Mind the Gap – Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence

    by Theresa Clare Noonan, Katrin Denzinger, Valerij Talagayev, Yu Chen, Kristina Puls, Clemens Alexander Wolf, Sijie Liu, Trung Ngoc Nguyen, Gerhard Wolber

    G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. 3D pharmacophore models are powerful computational tools in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and elucidation of ligand-receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning will be highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs.


  • The application of the MM/GBSA method in the binding pose prediction of FGFR inhibitors

    by Yu Chen, Yongxiang Zheng, Pedro Fong, Shengjun Mao, Qiantao Wang

    The correct conformation had lower MM/GBSA binding free energy in longer MD simulations for each FGFR1 inhibitor.


  • The performance comparison in predicting n-decane pyrolysis process between three ANNs methods: MLP, RBFN and GRNN

    by Chengang Yang, Zongjie Quan, Yu Chen, Quan Zhu, Jianli Wang, Xiangyuan Li

    In this work, three kinds of ANNs are employed to predict the pyrolysis behavior of n-decane. Six-fold cross validation method is adopted to optimize the key parameter of ANNs and evaluate the performance of ANNs. The results indicate that RBFN has best performance in predicting the species distribution and all ANNs have good performance in predicting the bulk temperature. Meanwhile, these results reveal that all ANNs are more suitable for predicting products with high mass fraction than those with less mass fraction, whose errors are also acceptable.